UNSPSC 51281911: Olivomycin b

This classification denotes a dna minor groove binding agent and antineoplastic antibiotic with the molecular formula C56H80O26, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FO0E69826C, chemically known as olivomycin d, 3d-o-(4-o-acetyl-2,6-dideoxy-3-c-methyl-.alpha.-l-arabino-hexopyranosyl)-, but more generally known as olivomycin b, which bears US NIH Compound Identifier 201840. European Medicines Agency schedules olivomycin b or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03507MIG.

Most nations, for tariff purposes, schedule olivomycin b under HS 29419000. SMILES:.

UNSPSC 51281911 Olivomycin B, a Commodity code, describes pharmaceutical active ingredients and specialty chemicals that state and local health agencies procure for clinical and therapeutic programs. Recent state and local activity under this code is minimal; the single recent opportunity on record is a Texas Health and Human Services Commission Request for Information (RFI) posted April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. That RFI targets pharmacy benefit management and direct contracting capacity rather than specific pharmaceutical commodities, and does not constitute a formal solicitation for olivomycin B or related active pharmaceutical ingredients. The code sees limited recent procurement activity from state and local issuing bodies, with no pattern of repeat buyers or sustained demand signals visible in current opportunity records.

Geographic spread and representative opportunities cannot be reliably characterized from available records. The Texas HHS Commission RFI represents the only recent state or local procurement tagged to this code, and its focus on contracting models and vendor capabilities rather than pharmaceutical procurement makes it an imperfect proxy for typical activity under the Commodity code. State and local procurement of pharmaceutical active ingredients such as olivomycin B, when it occurs, typically flows through state pharmacy benefit programs, Medicaid purchasing cooperatives, or health department procurement offices; however, no such solicitations appear in current records. The code warrants continued monitoring for future health agency RFPs or ITBs tied to specialty pharmaceutical supply or clinical program support, but immediate pursuit activity is not supported by recent opportunity signals.